about
Changes in monthly unemployment rates may predict changes in the number of psychiatric presentations to emergency services in South AustraliaThe National Mental Health Commission Report: Evidence based or ideologically driven?Mental health services reach the tipping point in Australian acute hospitals.Divided we fall: clinicians and academic psychiatrists need to stand together.The Royal Australian and New Zealand College of Psychiatrists guidelines: Acute inpatient care for schizophrenia.Workplace bullying in Australia: Recruiting ethical leaders is an important public health measure.Geography of primary mental health care through the Better Access initiative in South Australia 2006-2010.Agomelatine-induced akathisia in a 38-year-old woman with depression.Making sense of health care delivery Where does the close to community health care worker fit in? - The case for congestive heart failure.Potential antipsychotic effects of zolpidem.Cough syrup psychosis: Is it under-recognised?Youth hub-and-spoke model.Conversion Parkinson's disease with levodopa abuse and psychosis.Conversion disorder or multiple sclerosis?Neuropsychiatric aspects of frontal lobe meningioma.When should governments increase the supply of psychiatric beds?Mass incarceration and severe mental illness in the USA.Aripiprazole-induced neuroleptic malignant syndrome.Successful clozapine re-challenge following myocarditis.Why not rapid clozapine dose titration?Schizoaffective disorder, catatonia and white matter changes - Revisiting the microglial hypothesis.The clinical utility of therapeutic drug monitoring for clozapine.Lithium, suicide prevention and unipolar depression?The role of the GABAergic system in catatonia-Insights from clozapine and benzodiazepines.Firearm lobbying, suicide prevention, and the Trump presidency.Paediatric bipolar disorder: Reality or myth?Increasing the Use of Lithium and Clozapine in US Suicide Prevention.Bullying and depression at work: prevention starts at the very top.Psychiatric beds and increased suicide rates in England.Expert leadership - why psychiatrists should lead mental health services.Changes for clozapine monitoring in the United States.Cyclical suicidal ideation following natalizumab infusion for multiple sclerosis.The role of Transcranial Magnetic Stimulation in treatment resistant depression.Complicated management of mania in the setting of undiagnosed obstructive sleep apnea.Clozapine, immunosuppressants and renal transplantation.FDA changes clozapine monitoring guidelines: Implications for worldwide practice.McGorry et al. debate on the 'National Mental Health Commission Report: Evidence based or ideologically driven?'.St John's wort - Is it safe in Bipolar Disorder?Where is the clinical professor within the structure of regional mental health services?Rapid Response to Loading Dose Levothyroxine in Myxedema Psychosis.
P50
Q35709167-C69EC969-4E6D-4EE2-89A0-6C73A611C13FQ38596919-9EAE9C40-DB34-4A7B-B738-34D02D1B0254Q38665516-FD648D5B-A238-464C-8836-CF47A3D99472Q38682797-6131C643-DD27-42A7-8509-79C92A5FB809Q39408357-333CB458-E560-4611-842A-E97E19DBCD1AQ39586903-79CCB89B-1233-44B8-8EB4-198831EE770EQ40317479-CFE10F02-0174-46F2-8B93-53D59D7C5441Q41902942-A3F33FD0-C1ED-4B2A-8981-604CFE399E12Q42345821-4D240823-21A4-40B3-92C4-B87DDE2A95B6Q43180466-A8F705E2-7F39-4995-AE6D-1D887B8766ADQ43410900-1ACF2462-17E1-41F7-8F12-E4F0F50C7CBFQ44305375-6A057249-D531-4710-8E81-82AF73416ED3Q47616270-42AAD3FB-9289-478F-9787-0D16BE8AB1EFQ47652483-A55F5D78-0CC8-40CA-A289-E4668A2AB3AAQ47662849-5C8E7602-B20B-478B-912E-9534DFD98F3EQ47671205-C649C9E3-DAA4-4AE7-A3B3-7AB0F35A87D0Q47677053-5B3D6C0B-DEA4-4612-A313-23981AF7B8E6Q47709118-ECD1F6FC-17E7-4B67-8E59-BEC1DC077583Q47722361-633534E3-69EF-4B01-8049-057EBC31FB3FQ47728964-A192B830-FF02-4FF8-9F87-8719FE39EFE1Q47764694-AE81EC05-909E-4EB0-A93C-C943C4DB9690Q47860507-4FF22271-74CF-4939-B057-E1B7024260B2Q47860518-A4B3B290-3521-4018-B3CD-E741725EB35BQ47898916-56AE9A64-578C-4188-B97D-E98DD1FFC7C4Q47902412-7669DF5A-103B-4F72-8463-FAD9F0039A2CQ47927820-0888E041-8309-460D-988D-6A5AB59ADE54Q47959693-E5D1EFEA-C763-444A-83BE-7D1D0EBAD9DCQ47981903-3A600306-4AB0-4A2F-8593-0D36DAA51B37Q47990324-8E6B790B-165B-4C5E-8F25-F42BB0165B01Q48015524-53E699FD-DD62-4DB8-8995-69037160B7EFQ48032137-0E6804B6-7660-4700-9424-A80DBA957A81Q48113863-82DD25D0-4B71-4B3E-ADB7-20199162C5E4Q48148789-728FAEDB-5420-4E4E-8183-78243628B6FEQ48353528-5011B89A-E4EF-4216-862D-05A555C6A6C3Q48396020-22FFD5A2-8BB9-4E92-8EA1-83B173CB04DDQ48720687-34D73261-1224-4E6C-B1F9-7C7C98A19807Q50540941-1FED6991-DDDE-4D68-A46E-283C77C148F7Q50586127-C809499C-5303-462F-9E43-C1D77DDA4FAFQ50599907-6E391735-8DF2-4CA5-9353-B8B371DEE474Q50945418-89C1F6C6-19BE-4ADB-A3CE-F30F2B965C82
P50
description
researcher ORCID ID = 0000-0002-6931-2913
@en
name
Tarun Bastiampillai
@ast
Tarun Bastiampillai
@en
Tarun Bastiampillai
@es
Tarun Bastiampillai
@nl
type
label
Tarun Bastiampillai
@ast
Tarun Bastiampillai
@en
Tarun Bastiampillai
@es
Tarun Bastiampillai
@nl
prefLabel
Tarun Bastiampillai
@ast
Tarun Bastiampillai
@en
Tarun Bastiampillai
@es
Tarun Bastiampillai
@nl
P1153
6508023555
P31
P496
0000-0002-6931-2913